Oral phosphate binders: History and prospects

Bone

Volumn 45, Issue SUPPL. 1, 2009, Pages S8-

  Kazama, Junichiro James ^a  

^a NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

Author keywords

CKD MBD; Hyperphosphatemia; Lanthanum carbonate; Oral phosphate binders; Sevelamer hydrochloride

Indexed keywords

ALUMINUM HYDROXIDE; CALCIUM; LANTHANUM CARBONATE; PHOSPHATE; PHOSPHATE BINDING AGENT; RESIN;

ARTICLE; BLOOD VESSEL CALCIFICATION; CONSTIPATION; DRUG ABSORPTION; DRUG ELIMINATION; DRUG SAFETY; HUMAN;

EID: 67349188095     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.01.005     Document Type: Article

References (45)

1. Giachelli C.M., Jono S., Shioi A., Nishizawa Y., Mori K., and Morii H. Vascular calcification and inorganic phosphate. Am. J. Kidney Dis. 38 (2001) S34-S37
2. Jono S., McKee M.D., Murry C.E., Shioi A., Nishizawa Y., Mori K., et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ. Res. 87 (2000) E10-E17
3. Leypoldt J.K. Kinetics of beta2-microglobulin and phosphate during hemodialysis: effects of treatment frequency and duration. Semin. Dial. 18 (2005) 401-408
4. Freeman S., and Freeman W.M.C. Phosphate retention in children with chronic renal insufficiency-the effect of diet and of the ingestion of aluminum hydroxide. Am. J. Dis. Child. (1941) 981-1002
5. Ward M.K., Feest T.G., Ellis H.A., Parkinson I.S., and Kerr D.N. Osteomalacic dialysis osteodystrophy: evidence for a water-borne aetiological agent, probably aluminium. Lancet 8069 (1978) 841-845
6. Boyce B.F., Fell G.S., Elder N.Y., Junor B.J., Elliot H.L., Beastall G., et al. Hypercalcaemic osteomalacia due to aluminium toxicity. Lancet 8306 (1982) 1009-1013
7. Walker G.S., Aaron J.E., Peacock M., Robinson P.J., and Davison A.M. Dialysate aluminium concentration and renal bone disease. Kidney Int. 21 (1982) 411-415
8. MacDermott J.R., Smith A.I., Ward M.K., Parkinson I.S., and Kerr D.N. Brain-aluminium concentration in dialysis encephalopathy. Lancet 8070 (1978) 901-904
9. Hergesell O., and Rits E. Phosphate binders on iron basis: a new perspective?. Kidney Int. 73 (1999) S42-S45
10. Hsu C.H., Patel S.R., and Young E.W. New phosphate binding agents: ferric compounds. J. Am. Soc. Nephrol. 10 (1999) 1274-1280
11. Van de Vyver F.L., Visser W.J., D'Haese P.C., and De Broe M.E. Iron overload and bone disease in chronic dialysis patients. Nephrol. Dial Transplant. 5 (1990) 781-787
12. Kazama J.J., Arakawa M., Gejyo F., and Nakazawa R. Intraosteoblastic iron assimilation in two dialysis cases with iron overload. Nephrol. Dial Transp. 12 (1997) 2807-2808
13. Persy V.P., Behets G.J., Bervoets A.R., De Broe M.E., and D'Haese P.C. Lanthanum: a safe phosphate binder. Semin. Dial. 19 (2006) 195-199
14. Freemont A.J. Lanthanum carbonate. Drugs 42 (2006) 759-770
15. Slatopolsky E., Liapis H., and Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int. 68 (2005) 2809-2813
16. Lacour B., Lucas A., Auchere D., Ruellan N., de Serre Patey N.M., and Drueke T.B. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int. 67 (2005) 1062-1069
17. McLeod C., Cox A., and Bramall N. The need for contamination control in studies on lanthanum biodisposition. Kidney Int. 68 (2005) 2906-2907
18. Slatopolsky E., Weerts C., Lopez-Hilker S., Norwood K., Zink M., Windus D., et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N. Eng. J. Med. 315 (1986) 157-161
19. Watanabe H., Hiraishi H., Ishida M., Kazama J.J., and Terano A. Pathophysiology of gastric acid secretion in patients with chronic renal failure: influence of Helicobacter pylori infection. J. Intern. Med. 254 (2003) 439-446
20. Andress D.L. Adynamic bone in patients with chronic kidney disease. Kidney Int. 73 (2008) 1345-1354
21. Moe S.M., and Chertow G.M. The case against calcium-based phosphate binders. Clin. J. Am. Soc. Nephrol. 1 (2006) 697-703
22. Chertow G.M. Slowing the progression of vascular calcification in hemodialysis. J. Am. Soc. Nephrol. 14 (2003) S310-S314
23. Asmus H.G., Braun J., Krause R., Brunkhorst R., Holzer H., Sculz W., et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol. Dial. Transp. 20 (2005) 1653-1661
24. Braun J., Asmus H.G., Holzer H., Brunkhorst R., Krause R., Schulz W., et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate-phosphorus metabolism and cardiovascular calcification. Clin. Nephrol. 62 (2004) 104-115
25. Block G.A., Spiegel D.M., Ehrlich J., Mehta R., Lindbergh J., Dreisbach A., et al. Effect of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 68 (2005) 1815-1824
26. Spiegel D.M., Raggi P., Smits G., and Block G.A. Factors associated with mortality in patients new to haemodialysis. Nephrol. Dial. Transp. 22 (2007) 3568-3572
27. Block G.A., Raggi P., Ballasi A., Kooienga L., and Spiegel D.M. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 71 (2007) 438-441
28. Frazao J.M., and Adragao T. Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival data. Kidney Int. 74 S111 (2008) S34-S43
29. Moe S., Drueke T., Cunningham J., Goodman W., Martin K., Olgaard K., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease Improving Global Outcomes (KDIGO). Kidney Int. 69 (2006) 1945-1953
30. Friedman E.A. Calcium-based phosphate binders are appropriate in chronic renal failure. Clin. J. Am. Soc. Nephrol. 1 (2006) 704-709
31. Suki W.N., Zabaneh R., Cangiano J.L., Reed J., Fischer D., Garrett L., et al. Effect of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 72 (2007) 1130-1137
32. St Peter W.L., Liu J., Weinhandl E., and Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am. J. Kidney Dis. 51 (2008) 445-454
33. Qunibi W., Moustafa M., Muenz L.R., He D.Y., Kessler P.D., Diaz-Buxo J.A., et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am. J. Kidney Dis. 51 (2008) 952-965
34. Kazama J.J. Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism. Ther. Apher. Dial. 11 (2007) S44-S47
35. de Francisco A.L., Pinera C., Palomar R., and Arias M. Impact of treatment with calcimimetics on hyperparathyroidism and vascular mineralization. J. Am. Soc. Nephrol. 17 (2006) S281-S285
36. Tonelli M., Wiebe N., Culleton B., Lee H., Klarenbach S., Shrive F., et al. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol. Dial. Transp. 22 (2007) 2856-2866
37. Wilkes B.M., Reiner D., Kern M., and Burke S. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Clin. Nephrol. 50 (1998) 381-386
38. Rosenbaum D.P., Holmes-Farley S.R., Mandeville W.H., Pitruzzello M., and Goldberg D.I. Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats. Nephrol. Dial. Transp. 12 (1997) 961-964
39. Goldberg D.I., Dillon M.A., Slatopolsky E.A., Garrett B., Gray J.R., Marbury T., et al. Effect of RenaGel, a non-absorbed, calcium- and aluminum-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol. Dial. Transp. 13 (1998) 2303-2310
40. Slatopolsky E.A., Burke S.K., and Dillon M.A. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int. 55 (1999) 299-307
41. Chertow G.M., Burke S.K., Raggi P., and Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 62 (2002) 245-252
42. Ogata H., Koiwa F., Shishido K., and Kinugasa E. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management. Ther. Apher. Dial. 9 (2005) 11-15
43. Chitrakar R., Tezuka S., Sonoda A., Sakane K., Ooi K., and Hirotsu T. Adsorption of phosphate from seawater on calcined MgMn-layered double hydroxides. J. Colloid Interface Sci. 290 (2005) 45-51
44. Rankin B.J., Zhu H., Webb M., and Roberts N.B. The development and in-vitro evaluation of novel mixed metal hydroxy-carbonate compounds as phosphate binders. J. Pharm. Pharmacol. 53 (2001) 361-369
45. Rankin B.J., Thewles A., Lote C.J., Webb M., and Roberts N.B. The evaluation of novel mixed metal hydroxy-carbonates as phosphate binders: an in-vivo study in the rat. J. Pharm. Pharmacol. 53 (2001) 513-519